PMID- 11268491
OWN - NLM
STAT- MEDLINE
DCOM- 20010412
LR  - 20221207
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 20
IP  - 5C
DP  - 2000 Sep-Oct
TI  - New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine 
      plus amifostine support in advanced non small cell lung cancer: a phase II study.
PG  - 3999-4003
AB  - New triplet chemotherapy combinations are under investigation in advanced non 
      small cell lung cancer (NSCLC). Carboplatin, plus paclitaxel, plus gemcitabine is 
      among the most active and promising regimens. The use of more aggressive 
      chemotherapy in order to improve results can increase toxicity. Amifostine 
      (WR-2721) reduces toxicity of radiotherapy and chemotherapy and protects 
      selectively a number of normal, but not neoplastic, tissue. Based on this 
      background, we performed a phase II study on carboplatin, plus paclitaxel, plus 
      gemcitabine with amifostine support in advanced NSCLC. Patients received 
      chemotherapy at the following dosage: carboplatin AUC 5, i.v., at day 1; 
      paclitaxel 175 mg/m2, i.v. by 3-hour infusion, at day 1; gemcitabine 1000 mg/m2, 
      i.v. by 3-hour infusion, at days 1 and 8; every 3 weeks for a maximum of 6 
      cycles. Amifostine was administered at the dose of 740 mg/m2, i.v., at day 1 of 
      each cycle. Seventeen patients entered the study. They were prevalently male, 
      median age was 62 years, PS (ECOG) was 0 in 10 cases (58.8%), 1 in 6 (35.3%) and 
      2 in 1 (5.9%). Histology was epidermoid in 8 cases (47%) and adenocarcinoma in 9 
      (53%). We observed 8 (47.5%) objective responses with 2 (11.7%) complete 
      responses. Median time to progression and median survival were 24 and 36 weeks, 
      respectively. Treatment was well tolerated. The main toxicity was as follows: 
      grade 3 neutropenia, grade 2 thrombocytopenia and grade 3 anemia in one (5.8%) 
      case; grade 2 peripheral neurologic toxicity in 3 (17.6%) patients; grade 2 
      cardiac toxicity (atrial fibrillation) in one case; and grade 3 respiratory 
      toxicity (dispnoea) in one patient. These data indicate that this combination has 
      promising activity and tolerability. A randomized trial comparing carboplatin 
      plus paclitaxel, plus gemcitabine versus carboplatin, plus paclitaxel, plus 
      gemcitabine, plus amifostine in advanced NSCLC is warranted.
FAU - Illiano, A
AU  - Illiano A
AD  - VI Divisione di Pneumologia, Ospedale Monaldi, Napoli, Italy.
FAU - Barletta, E
AU  - Barletta E
FAU - De Marino, V
AU  - De Marino V
FAU - Battiloro, C
AU  - Battiloro C
FAU - Barzelloni, M
AU  - Barzelloni M
FAU - Scognamiglio, F
AU  - Scognamiglio F
FAU - Rossi, N
AU  - Rossi N
FAU - Zampa, G
AU  - Zampa G
FAU - De Bellis, M
AU  - De Bellis M
FAU - Gridelli, C
AU  - Gridelli C
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Radiation-Protective Agents)
RN  - 0W860991D6 (Deoxycytidine)
RN  - BG3F62OND5 (Carboplatin)
RN  - M487QF2F4V (Amifostine)
RN  - P88XT4IS4D (Paclitaxel)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adenocarcinoma/drug therapy/pathology
MH  - Aged
MH  - Amifostine/administration & dosage/adverse effects/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Carcinoma, Squamous Cell/drug therapy/pathology
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Paclitaxel/administration & dosage
MH  - Radiation-Protective Agents/administration & dosage/adverse effects/therapeutic 
      use
MH  - Gemcitabine
EDAT- 2001/03/28 10:00
MHDA- 2001/04/17 10:01
CRDT- 2001/03/28 10:00
PHST- 2001/03/28 10:00 [pubmed]
PHST- 2001/04/17 10:01 [medline]
PHST- 2001/03/28 10:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 2000 Sep-Oct;20(5C):3999-4003.